United Super Pty Ltd in its capacity as Trustee for the Construction & Building Unions Superannuation Fund Increases Stock Holdings in Gilead Sciences, Inc. $GILD

United Super Pty Ltd in its capacity as Trustee for the Construction & Building Unions Superannuation Fund lifted its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 1,679.0% in the fourth quarter, HoldingsChannel reports. The firm owned 450,096 shares of the biopharmaceutical company’s stock after buying an additional 424,796 shares during the period. United Super Pty Ltd in its capacity as Trustee for the Construction & Building Unions Superannuation Fund’s holdings in Gilead Sciences were worth $55,245,000 at the end of the most recent quarter.

A number of other hedge funds have also recently modified their holdings of the company. Paulson Wealth Management Inc. grew its holdings in shares of Gilead Sciences by 1.8% in the fourth quarter. Paulson Wealth Management Inc. now owns 3,887 shares of the biopharmaceutical company’s stock valued at $477,000 after purchasing an additional 67 shares during the period. Alpha Cubed Investments LLC grew its holdings in shares of Gilead Sciences by 1.1% in the fourth quarter. Alpha Cubed Investments LLC now owns 6,619 shares of the biopharmaceutical company’s stock valued at $812,000 after purchasing an additional 75 shares during the period. Personal CFO Solutions LLC grew its holdings in shares of Gilead Sciences by 1.7% in the fourth quarter. Personal CFO Solutions LLC now owns 4,572 shares of the biopharmaceutical company’s stock valued at $561,000 after purchasing an additional 76 shares during the period. Moss Adams Wealth Advisors LLC grew its holdings in shares of Gilead Sciences by 1.7% in the fourth quarter. Moss Adams Wealth Advisors LLC now owns 4,446 shares of the biopharmaceutical company’s stock valued at $546,000 after purchasing an additional 76 shares during the period. Finally, Valued Wealth Advisors LLC grew its holdings in shares of Gilead Sciences by 12.5% in the fourth quarter. Valued Wealth Advisors LLC now owns 711 shares of the biopharmaceutical company’s stock valued at $87,000 after purchasing an additional 79 shares during the period. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on GILD. Wells Fargo & Company upped their price objective on shares of Gilead Sciences from $150.00 to $165.00 and gave the company an “overweight” rating in a report on Wednesday, February 11th. Royal Bank Of Canada dropped their price objective on shares of Gilead Sciences from $123.00 to $122.00 and set a “sector perform” rating for the company in a report on Friday, May 8th. Needham & Company LLC reaffirmed a “buy” rating and set a $170.00 target price on shares of Gilead Sciences in a research note on Monday, February 23rd. Truist Financial reaffirmed a “buy” rating and set a $157.00 target price (up from $155.00) on shares of Gilead Sciences in a research note on Friday, May 8th. Finally, Scotiabank increased their target price on shares of Gilead Sciences from $140.00 to $177.00 and gave the stock a “sector outperform” rating in a research note on Wednesday, February 11th. Twenty-five research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $156.93.

Insider Transactions at Gilead Sciences

In other news, insider Johanna Mercier sold 28,000 shares of the stock in a transaction dated Friday, May 15th. The shares were sold at an average price of $131.29, for a total transaction of $3,676,120.00. Following the sale, the insider owned 125,779 shares of the company’s stock, valued at approximately $16,513,524.91. This represents a 18.21% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Andrew D. Dickinson sold 3,000 shares of the stock in a transaction dated Friday, May 15th. The stock was sold at an average price of $132.27, for a total transaction of $396,810.00. Following the sale, the chief financial officer directly owned 173,191 shares in the company, valued at $22,907,973.57. This represents a 1.70% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 53,000 shares of company stock valued at $7,075,670. 0.30% of the stock is currently owned by corporate insiders.

Gilead Sciences Stock Up 1.9%

Shares of GILD opened at $136.22 on Friday. The stock has a market capitalization of $169.13 billion, a PE ratio of 18.56 and a beta of 0.31. Gilead Sciences, Inc. has a 1 year low of $104.46 and a 1 year high of $157.29. The company has a debt-to-equity ratio of 0.89, a quick ratio of 1.77 and a current ratio of 1.97. The company’s 50-day simple moving average is $135.43 and its 200-day simple moving average is $134.08.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings results on Thursday, May 7th. The biopharmaceutical company reported $2.03 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.91 by $0.12. The business had revenue of $6.96 billion for the quarter, compared to analysts’ expectations of $6.91 billion. Gilead Sciences had a net margin of 30.99% and a return on equity of 48.19%. The business’s quarterly revenue was up 4.4% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.81 earnings per share. Gilead Sciences has set its FY 2026 guidance at -1.050–0.650 EPS. Analysts forecast that Gilead Sciences, Inc. will post -0.79 earnings per share for the current fiscal year.

Gilead Sciences Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Monday, June 29th. Stockholders of record on Monday, June 15th will be given a dividend of $0.82 per share. This represents a $3.28 annualized dividend and a dividend yield of 2.4%. The ex-dividend date of this dividend is Monday, June 15th. Gilead Sciences’s dividend payout ratio is currently 44.69%.

Gilead Sciences Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.